Longevity.Technology (@LongevityTech)· LongevityTech·· 6 天前评分12
韩生物科技TLY012靶向疤痕细胞
TLY012 targets the cells responsible for building scar tissue, with the Korean biotech expecting Phase 1 to begin in the first half of 2027.
导读
TLY012靶向负责构建疤痕组织的细胞,这家韩国生物科技公司预计Phase 1将于2027年上半年启动。 https://vist.ly/5syrd #longevity #geroscience #fibrosis #biotech #clinicaltrials
来源:Longevity.Technology (@LongevityTech) · x.com